Erythropoietin in HIE Neonate

ConditionNeonatal Hypoxic Ischemic Encephalopathy

Trial statusNot yet recruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age1-1

SponsorAssiut University

About this trial

this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal hypoxic ischemic encephalopathy?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

neonates who more than 1 month

neonates who suffer from brain insults other than HIE

Trial design

Design model

Single group

Treatments tested in this trial

Erythropoietin
Drug
the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy

Treatment groups

3 Participants

are divided into 3 treatment groups

Group A: to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathyExperimental treatment 1 intervention

Group B: Role of Erythropoietin in neonate hypoxic ishemic encephalopathyOther 1 intervention

Group C: Role of Erythropoietin in neonatal hypoxic ischemic encephalopathyNo intervention 0 interventions

Trial outcomes

Primary outcomes

oxygen saturation in neonates hypoxic ischemic encephalopathy after treatment byerythropoietin

EPO provides a mechanism to maintain or re-establish the function of all other cells in challenging physiological conditions e.g., hypoxia

Time frame

Baseline

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: